Eye-Preserving Therapies for Early cT3c Retinoblastoma.
Eye-preserving treatment saved the eye in nearly half of early cT3c retinoblastoma cases.
Eye-Preserving Therapies for Early cT3c Retinoblastoma.
To evaluate the safety and effectiveness of eye-preserving therapies in patients with American Joint Committee on Cancer (AJCC) eighth edition cT3c retinoblastoma presenting with neovascular glaucoma (neovascular glaucoma) without buphthalmos (defined as early cT3c), focusing on overall survival and eye preservation.
132 patients diagnosed with early cT3c retinoblastoma from May 2014 through October 2024.
Eye-preserving therapies were associated with a lower incidence of high-risk pathological features (odds ratio [OR], 0.21; P = 0.003), with attenuated severity of both choroidal (OR, 0.25; P = 0.002) and optic nerve invasion (OR, 0.23; P = 0.008).
And among these preserved eyes, 46.3% (19/41) regained light projection or better after receiving eye-preserving therapies.
Importantly, presenting intraocular pressure (IOP) ≥32 mmHg (hazard ratio [HR], 2.37; P = 0.010) and corneal edema (HR, 2.86; P = 0.007) were high risk factors for globe salvage failure.
Primary eye-preserving therapies can secure high rates of globe salvage with partial visual function in patients with early cT3c retinoblastoma, without jeopardizing patient survival.
However, eyes exhibiting corneal edema or IOP ≥32 mmHg demonstrate markedly inferior salvage outcomes, the treatment strategy for such patients must therefore be cautiously individualized.